An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Chronic Kidney Disease Not On Dialysis

Roche

Status: Completed

Conditions: Kidney Disease, Chronic

Study type: Observational

Funder types: Industry

Identifiers

NCT01318512

ML25317

Details and patient eligibility

About

This observational, prospective, multicenter study will describe the mean dose of Mircera (methoxy polyethylene glycol-epoetin beta) and the hemoglobin levels in patients with chronic kidney disease. Patients are not on dialysis and are naive to, or have received erythropoiesis stimulating agent treatment. Data will be collected for 10 months.

Enrollment: 340 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults patients, >/=18 years of age
• Presence of chronic kidney disease (Stage 3-4)

Exclusion criteria

• Participation in another clinical study

Trial design

340 participants in 1 patient group

Chronic Kidney Disease

Description:

Participants with CKD, not undergoing haemodialysis in clinical practice setting and started treatment with methoxy polyethylene glycol-epoetin beta (MIRCERA) subcutaneously (SC) as per summary of product characteristics (SPC) due to decreased levels of haemoglobin.